A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin.
Emens
Leisha A
LA
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231-2410, USA. emensle@jhmi.edu
Armstrong
Deborah
D
Biedrzycki
Barbara
B
Davidson
Nancy
N
Davis-Sproul
Janice
J
Fetting
John
J
Jaffee
Elizabeth
E
Onners
Beth
B
Piantadosi
Steve
S
Reilly
Richard T
RT
Stearns
Vered
V
Tartakovsky
Irena
I
Visvanathan
Kala
K
Wolff
Antonio
A
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D019496:Cancer Vaccines / Q000009:adverse effects* / Q000235:genetics / Q000276:immunology; D045744:Cell Line, Tumor; D002985:Clinical Protocols; D017321:Clinical Trials, Phase I as Topic / Q000379:methods*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000235:genetics* / Q000276:immunology / Q000378:metabolism; D006801:Humans; D051379:Mice
D019496:Cancer Vaccines; D004317:Doxorubicin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide